Anmelden Kostenlos registrieren

Kazia Therapeutics Operative Marge

Was ist das Operative Marge von Kazia Therapeutics?

Operative Marge von Kazia Therapeutics Limited ist -248,657.00%

Was ist die Definition von Operative Marge?



Die operative Marge ist das Verhältnis von Betriebseinkommen zu Nettomsatz und in Prozent dargestellt.

Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.

Operative Marge von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Kazia Therapeutics

Was macht Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Unternehmen mit operative marge ähnlich Kazia Therapeutics